FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W945208301> ?p ?o ?g. }

• W945208301 endingPage "560" @default.
• W945208301 startingPage "541" @default.
• W945208301 abstract "To determine if photodynamic therapy with verteporfin (Visudyne; Novartis AG, Bülach, Switzerland), termed verteporfin therapy, can safely reduce the risk of vision loss compared with a placebo (with sham treatment) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration who were identified with a lesion composed of occult with no classic choroidal neovascularization, or with presumed early onset classic choroidal neovascularization with good visual acuity letter score.This was a double-masked, placebo-controlled (sham treatment), randomized, multicenter clinical trial involving 28 ophthalmology practices in Europe and North America. The study population was patients with age-related macular degeneration, with subfoveal choroidal neovascularization lesions measuring no greater than 5400 microm in greatest linear dimension with either 1) occult with no classic choroidal neovascularization, best-corrected visual acuity score of at least 50 (Snellen equivalent approximately 20/100), and evidence of hemorrhage or recent disease progression; or 2) evidence of classic choroidal neovascularization with a best-corrected visual acuity score of at least 70 (better than a Snellen equivalent of approximately 20/40); assigned randomly (2:1) to verteporfin therapy or placebo therapy. Verteporfin (6 mg per square meter of body surface area) or placebo (5% dextrose in water) was administered by means of intravenous infusion of 30 ml over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm delivered 50 J/cm(2) by application of an intensity of 600 mW/cm(2) over 83 seconds using a spot size with a diameter 1000 microm larger than the greatest linear dimension of the choroidal neovascularization lesion on the retina. At follow-up examinations every 3 months, retreatment with the same regimen was applied if angiography showed fluorescein leakage. The main outcome measure was at least moderate vision loss, that is, a loss of at least 15 letters (approximately 3 lines), adhering to an intent-to-treat analysis with the last observation carried forward to impute for missing data.Two hundred ten (93%) and 193 (86%) of the 225 patients in the verteporfin group compared with 104 (91%) and 99 (87%) of the 114 patients in the placebo group completed the month 12 and 24 examinations, respectively. On average, verteporfin-treated patients received five treatments over the 24 months of follow-up. The primary outcome was similar for the verteporfin-treated and the placebo-treated eyes through the month 12 examination, although a number of secondary visual and angiographic outcomes significantly favored the verteporfin-treated group. Between the month 12 and 24 examinations, the treatment benefit grew so that by the month 24 examination, the verteporfin-treated eyes were less likely to have moderate or severe vision loss. Of the 225 verteporfin-treated patients, 121 (54%) compared with 76 (67%) of 114 placebo-treated patients lost at least 15 letters (P =.023). Likewise, 67 of the verteporfin-treated patients (30%) compared with 54 of the placebo-treated patients (47%) lost at least 30 letters (P =.001). Statistically significant results favoring verteporfin therapy at the month 24 examination were consistent between the total population and the subgroup of patients with a baseline lesion composition identified as occult choroidal neovascularization with no classic choroidal neovascularization. This subgroup included 166 of the 225 verteporfin-treated patients (74%) and 92 of the 114 placebo-treated patients (81%). In these patients, 91 of the verteporfin-treated group (55%) compared with 63 of the placebo-treated group (68%) lost at least 15 letters (P =.032), whereas 48 of the verteporfin-treated group (29%) and 43 of the placebo-treated group (47%) lost at least 30 letters (P =.004). Other secondary outcomes, including visual acuity letter score worse than 34 (approximate Snellen equivalent of 20/200 or worse), mean change in visual acuity letter score, development of classic choroidal neovascularization, progression of classic choroidal neovascularization and size of lesion, favored the verteporfin-treated group at both the month 12 and month 24 examination for both the entire study group and the subgroup of cases with occult with no classic choroidal neovascularization at baseline. Subgroup analyses of lesions composed of occult with no classic choroidal neovascularization at baseline suggested that the treatment benefit was greater for patients with either smaller lesions (4 disc areas or less) or lower levels of visual acuity (letter score less than 65, an approximate Snellen equivalent of 20/50(-1) or worse) at baseline. Prospectively planned multivariable analyses confirmed that these two baseline variables affected the magnitude of treatment benefit. (ABSTRACT TRUNCATED)" @default.
• W945208301 created "2016-06-24" @default.
• W945208301 creator A5072357388 @default.
• W945208301 date "2001-05-01" @default.
• W945208301 modified "2023-10-18" @default.
• W945208301 title "Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2" @default.
• W945208301 cites W1601975653 @default.
• W945208301 cites W2133251726 @default.
• W945208301 cites W2157389251 @default.
• W945208301 cites W4242385022 @default.
• W945208301 cites W4242893149 @default.
• W945208301 doi "https://doi.org/10.1016/s0002-9394(01)00967-9" @default.
• W945208301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11336929" @default.
• W945208301 hasPublicationYear "2001" @default.
• W945208301 type Work @default.
• W945208301 sameAs 945208301 @default.
• W945208301 citedByCount "739" @default.
• W945208301 countsByYear W9452083012012 @default.
• W945208301 countsByYear W9452083012013 @default.
• W945208301 countsByYear W9452083012014 @default.
• W945208301 countsByYear W9452083012015 @default.
• W945208301 countsByYear W9452083012016 @default.
• W945208301 countsByYear W9452083012017 @default.
• W945208301 countsByYear W9452083012018 @default.
• W945208301 countsByYear W9452083012019 @default.
• W945208301 countsByYear W9452083012020 @default.
• W945208301 countsByYear W9452083012021 @default.
• W945208301 countsByYear W9452083012022 @default.
• W945208301 countsByYear W9452083012023 @default.
• W945208301 crossrefType "journal-article" @default.
• W945208301 hasAuthorship W945208301A5072357388 @default.
• W945208301 hasConcept C118487528 @default.
• W945208301 hasConcept C126322002 @default.
• W945208301 hasConcept C141071460 @default.
• W945208301 hasConcept C142724271 @default.
• W945208301 hasConcept C204787440 @default.
• W945208301 hasConcept C27081682 @default.
• W945208301 hasConcept C2776403814 @default.
• W945208301 hasConcept C2778257484 @default.
• W945208301 hasConcept C2778271429 @default.
• W945208301 hasConcept C2778348428 @default.
• W945208301 hasConcept C2780394083 @default.
• W945208301 hasConcept C2781148688 @default.
• W945208301 hasConcept C2781359195 @default.
• W945208301 hasConcept C2908647359 @default.
• W945208301 hasConcept C71924100 @default.
• W945208301 hasConcept C99454951 @default.
• W945208301 hasConceptScore W945208301C118487528 @default.
• W945208301 hasConceptScore W945208301C126322002 @default.
• W945208301 hasConceptScore W945208301C141071460 @default.
• W945208301 hasConceptScore W945208301C142724271 @default.
• W945208301 hasConceptScore W945208301C204787440 @default.
• W945208301 hasConceptScore W945208301C27081682 @default.
• W945208301 hasConceptScore W945208301C2776403814 @default.
• W945208301 hasConceptScore W945208301C2778257484 @default.
• W945208301 hasConceptScore W945208301C2778271429 @default.
• W945208301 hasConceptScore W945208301C2778348428 @default.
• W945208301 hasConceptScore W945208301C2780394083 @default.
• W945208301 hasConceptScore W945208301C2781148688 @default.
• W945208301 hasConceptScore W945208301C2781359195 @default.
• W945208301 hasConceptScore W945208301C2908647359 @default.
• W945208301 hasConceptScore W945208301C71924100 @default.
• W945208301 hasConceptScore W945208301C99454951 @default.
• W945208301 hasIssue "5" @default.
• W945208301 hasLocation W9452083011 @default.
• W945208301 hasLocation W9452083012 @default.
• W945208301 hasOpenAccess W945208301 @default.
• W945208301 hasPrimaryLocation W9452083011 @default.
• W945208301 hasRelatedWork W1018929170 @default.
• W945208301 hasRelatedWork W163452782 @default.
• W945208301 hasRelatedWork W1990384334 @default.
• W945208301 hasRelatedWork W2085712747 @default.
• W945208301 hasRelatedWork W2128574114 @default.
• W945208301 hasRelatedWork W2320771024 @default.
• W945208301 hasRelatedWork W2329828213 @default.
• W945208301 hasRelatedWork W2917472240 @default.
• W945208301 hasRelatedWork W2991715136 @default.
• W945208301 hasRelatedWork W4241671912 @default.
• W945208301 hasVolume "131" @default.
• W945208301 isParatext "false" @default.
• W945208301 isRetracted "false" @default.
• W945208301 magId "945208301" @default.
• W945208301 workType "article" @default.